Analysts Issue Forecasts for Nuvation Bio Q1 Earnings

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Nuvation Bio in a report released on Friday, August 7th. HC Wainwright analyst R. Burns anticipates that the company will earn $0.01 per share for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.11) EPS.

Other equities analysts have also recently issued reports about the company. Royal Bank Of Canada increased their target price on Nuvation Bio from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday. Truist Financial upped their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a research note on Wednesday, June 10th. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Thursday, July 23rd. Finally, B. Riley Financial reissued a “buy” rating on shares of Nuvation Bio in a research report on Friday. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Nuvation Bio Trading Down 3.0%

NYSE NUVB opened at $6.40 on Monday. The company has a quick ratio of 8.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.96. Nuvation Bio has a 52 week low of $2.21 and a 52 week high of $9.75. The business has a 50 day moving average price of $5.82 and a 200-day moving average price of $5.24. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -14.55 and a beta of 1.52.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Nuvation Bio had a negative net margin of 88.18% and a negative return on equity of 46.59%. The firm had revenue of $31.69 million during the quarter, compared to analyst estimates of $27.03 million.

Insider Buying and Selling

In related news, insider Kerry Wentworth sold 63,000 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.02, for a total value of $379,260.00. Following the completion of the sale, the insider directly owned 53,000 shares of the company’s stock, valued at approximately $319,060. This represents a 54.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal acquired 25,000 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were bought at an average price of $4.73 per share, for a total transaction of $118,250.00. Following the completion of the purchase, the director owned 225,000 shares in the company, valued at approximately $1,064,250. This represents a 12.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 235,668 shares of company stock worth $1,419,495 in the last ninety days. Corporate insiders own 30.11% of the company’s stock.

Institutional Trading of Nuvation Bio

Several institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC boosted its holdings in shares of Nuvation Bio by 9.8% in the 4th quarter. HighTower Advisors LLC now owns 22,457 shares of the company’s stock worth $201,000 after buying an additional 2,007 shares during the last quarter. Tema ETFs LLC increased its holdings in Nuvation Bio by 0.7% during the second quarter. Tema ETFs LLC now owns 395,313 shares of the company’s stock worth $2,245,000 after buying an additional 2,559 shares during the last quarter. Parallel Advisors LLC raised its position in Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after acquiring an additional 2,597 shares during the period. Russell Investments Group Ltd. raised its position in Nuvation Bio by 17.7% in the fourth quarter. Russell Investments Group Ltd. now owns 24,456 shares of the company’s stock worth $219,000 after acquiring an additional 3,681 shares during the period. Finally, Meridian Wealth Management LLC raised its position in Nuvation Bio by 3.8% in the fourth quarter. Meridian Wealth Management LLC now owns 113,565 shares of the company’s stock worth $1,018,000 after acquiring an additional 4,200 shares during the period. Institutional investors own 61.67% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.